| RIPRETINIB | None | ||
| 50MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. | |||
|
Yes
| |||
| QINLOCK | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | Patent 32 | Patent 33 | Patent 34 | Patent 35 | Patent 36 | Patent 37 | Patent 38 | Patent 39 | Patent 40 | Patent 41 | Patent 42 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||||||||||||||||||||||||
| ************************, ******************** *** ******* ********* ****** ** ****** ********** *** *** ********* ** ************* ******** | ********************* *** ******* ********* ****** ** ****** ********** *** *** ********* ** ************* ******** | ********************* *** ******* ********* ****** ** ****** ********** *** *** ********* ** ************* ******** | ******* ** ******** **************** ******* ****** | ********* ****** ********* ************ *** ******* ** *** ******* | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-************)-*-********** | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ********* ****** ********* ************ *** ******* ** *** ******* | ******* ** ******** **************** ******* ****** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-************)-*-********** | ******* ** ******** **************** ******* ****** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-************)-*-********** | ********* ****** ********* ************ *** ******* ** *** ******* | ******* ** ******** **************** ******* ****** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-************)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ******* ** ******** **************** ******* ****** | (***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ******* ** ******** **************** ******* ****** | ******* ** ******** **************** ******* ****** | ************ ** *-(*-*****-*-(*-*****-*-(***********)-*-***-*,*-*******-*,*-************-*-**)-*-***********)-*-********** | ********************* *** ******* ********* ****** ** ****** ********** *** *** ********* ** ************* ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|